Thymosin Beta-4 — questions, answered plainly.

Thymosin Beta-4 (Tβ4) is a naturally occurring 43-residue actin-binding peptide expressed in many human tissues. It is encoded by the TMSB4X gene and has been studied in cell biology, rodent, human-organoid, and limited early-phase clinical contexts.

Tβ4 is the primary intracellular sequestrant of monomeric (G-)actin in mammalian cells. By holding G-actin in a non-polymerised form, Tβ4 helps regulate the actin cytoskeleton and downstream processes like cellular migration.

No. TB-500 is a commercial name often applied to synthetic Tβ4 sold for research use. Native Tβ4 (the endogenous peptide) and TB-500-marketed material are not equivalent to approved therapeutics, and synthetic products vary in purity.

The PubMed-indexed work referenced here spans a narrative review of Tβ4 and Tβ10 expression in human organs (Faa et al. 2024), a mouse cardiac-remodelling study (Maar et al. 2025), and a human iPSC organoid + 5xFAD mouse Alzheimer's study (Zeng et al. 2025). No controlled human trial of Tβ4 is cited on this profile.

Several studies, including Maar et al. 2025, have associated Tβ4 with cardiac remodelling pathways in mouse infarction models, including ROCK1 modulation and miRNA expression changes. These are preclinical observations and do not establish clinical efficacy.

Although Tβ4 is endogenously expressed in humans, synthetic products marketed under names such as TB-500 are not equivalent to approved therapeutics. Findings from organoid and rodent models do not establish clinical efficacy or safety.